ALGN vs EW Comparison: AI Score, Valuation, Performance and Upside
Compare Align Technology's Invisalign-driven orthodontics business against Edwards Lifesciences' structural heart devices.
Use this Align Technology vs Edwards Lifesciences comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
ALGN holds the edge across 3 of 5 key metrics in this comparison. ALGN leads on both 1-year return (+19.86%) and forward P/E quality (12.56x vs 26.71x for EW), a relatively favorable combination of momentum and valuation. EW leads on both revenue growth (13.60%) and operating margin (29.84%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for ALGN (+32.38%) than for EW (+11.92%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
| Metric | ALGN | EW |
|---|---|---|
| AI scorei | 39.0 | 42.2 |
| AI ranki | #1260 | #929 |
| Latest closei | $158.64 | $89.90 |
| 1M returni | -9.26% | +1.05% |
| 6M returni | -9.66% | +7.16% |
| 1Y returni | +19.86% | +10.69% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ALGN | EW |
|---|---|---|
| 1Y ago | $11.78K (+17.8%) started 2025-09-04 | $11.1K (+11.0%) started 2025-09-04 |
| 5Y ago | $2.21K (-77.9%) started 2021-09-07 | $7.37K (-26.3%) started 2021-09-07 |
| 10Y ago | $16.65K (+66.5%) started 2016-09-06 | $22.95K (+129.5%) started 2016-09-06 |
Hypothetical — past performance does not guarantee future results.
| Metric | ALGN | EW |
|---|---|---|
| Market capi | $11.19B | $52B |
| Trailing P/Ei | 27.31 | 53.70 |
| Forward P/Ei | 12.56 | 26.71 |
| Price/Salesi | 3.29 | N/A |
| EV/Revenuei | 2.47 | 7.46 |
| Analyst targeti | $208.60 | $100.96 |
| Target upsidei | +32.38% | +11.92% |
| Metric | ALGN | EW |
|---|---|---|
| Revenue growthi | 4.30% | 13.60% |
| Earnings growthi | -12.10% | -25.40% |
| EPS growthi | -12.10% | -25.40% |
| FCF margini | +14.12% | +18.92% |
| Operating margini | 18.25% | 29.84% |
| Profit margini | 9.99% | 15.43% |
| ROIC proxyi | 10.15% | 9.18% |
| Return on equityi | 10.15% | 9.18% |
| Dividend yieldi | N/A | N/A |
| Betai | 1.65 | 0.85 |
| Debt/equityi | 2.85 | 6.57 |
| Current ratioi | 1.40 | 4.52 |
| Quick ratioi | 1.20 | 3.45 |
Over the past year, ALGN and EW have moved weakly in the same direction (correlation of 0.25), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | ALGN | EW |
|---|---|---|---|
| 1Y | Growthi | +17.77% | +11.04% |
| CAGRi | +17.80% | +11.06% | |
| Volatilityi | 39.17% | 24.49% | |
| Sharpe ratioi | 0.50 | 0.37 | |
| Sortino ratioi | 0.75 | 0.55 | |
| Max drawdowni | 21.54% | 13.19% | |
| Current drawdowni | 19.68% | 5.55% | |
| Avg drawdowni | 8.20% | 4.58% | |
| Ulcer Indexi | 10.02% | 5.65% | |
| Max daily dropi | 6.91% | 3.64% | |
| Max wkly dropi | 10.35% | 7.40% | |
| 5Y | Growthi | -77.85% | -26.31% |
| CAGRi | -26.06% | -5.93% | |
| Volatilityi | 49.96% | 32.71% | |
| Sharpe ratioi | -0.44 | -0.15 | |
| Sortino ratioi | -0.59 | -0.19 | |
| Max drawdowni | 82.89% | 54.32% | |
| Current drawdowni | 78.27% | 31.21% | |
| Avg drawdowni | 62.53% | 34.33% | |
| Ulcer Indexi | 65.10% | 36.37% | |
| Max daily dropi | 36.63% | 31.34% | |
| Max wkly dropi | 36.19% | 30.43% | |
| 10Y | Growthi | +66.53% | +129.45% |
| CAGRi | +5.24% | +8.67% | |
| Volatilityi | 49.38% | 32.23% | |
| Sharpe ratioi | 0.26 | 0.29 | |
| Sortino ratioi | 0.37 | 0.39 | |
| Max drawdowni | 82.89% | 54.32% | |
| Current drawdowni | 78.27% | 31.21% | |
| Avg drawdowni | 39.70% | 20.99% | |
| Ulcer Indexi | 49.13% | 26.79% | |
| Max daily dropi | 36.63% | 31.34% | |
| Max wkly dropi | 36.19% | 30.43% |
| Category | ALGN | EW |
|---|---|---|
| Company | ALGN | EW |
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments & Supplies | Medical Devices |
| Core business | Align Technology, Inc. provides Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services in the United States, Switzerland, and internationally. | Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.